Dup15q Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Dup15q Syndrome Market Outlook
Thelansis’s “Dup15q Syndrome Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Dup15q Syndrome treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Dup15q
Syndrome Overview
Duplication
syndrome on chromosome 15q11.2-13.1, also known as Dup15q Syndrome, results
from extra genetic material in the 15q11.2-13.1 region, sometimes referred to
as the Prader-Willi/Angelman critical region (PWACR). This syndrome is
clinically identifiable and is characterized by symptoms such as hypotonia,
motor delays, intellectual disability, autism spectrum disorder (ASD), and
epilepsy, including infantile spasms. In rare cases, maternal Dup15q may also
lead to psychosis or unexplained death. Approximately 30 percent of individuals
with Dup15q Syndrome have strabismus (crossed eyes), and about 20-30 percent
experience growth-related issues resulting in smaller stature. Hypotonia tends
to improve with age, and in some cases, it may progress to hypertonia,
especially in the lower legs. Other associated problems include reduced pain
sensitivity, scoliosis, recurrent childhood respiratory infections, precocious
puberty, menstrual irregularities in females, minor genital abnormalities in
males, overeating, and excessive weight gain.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment